Studies have shown that pigmentation issues affect a large proportion of the world’s population, with 50% of people reporting at least one pigmentation disorder, including age spots, sunspots and post-inflammatory hyperpigmentation.

To target this important issue L’Oréal scientists developed Melasyl™, a patented new molecule, born from almost of 20 years of research, which helps to reduce the appearance of localized excess pigmentation and improve skintone uniformity.

Melasyl™ has a different mechanism of action from other cosmetic ingredients that act on localized hyperpigmentation.  It does not act on the enzyme responsible for melanin synthesis, and so does not permanently alter the natural biological pathways of skin pigment production responsible for skin color.

As a result, it's the first molecule to act on localized excess pigmentation by capturing melanin precursors - before they transform into eumelanin or pheomelanin, highly colored pigments liable to accumulate excessively and mark the skin.

Drawing on its dermatological expertise, La Roche-Posay has incorporated Melasyl™ into its Mela B3 range, now available in nearly 40 countries. The combination of the Mela B3 serum and an SPF30 cream offers an inclusive preventive routine to correct dark spots while protecting skin from UV exposure, an aggravating factor in hyperpigmentation.

Validated by over 121 scientific studies, Melasyl™ has proven its effectiveness in correcting localised pigmentation, regardless of skin colour.